Please listen in as Ron Silverman, MD discusses how PREVENA™ Incision Management System has been newly indicated by the FDA to aid in the reduction of seromas and to aid high risk patients by reducing the incidence of SSI’s in Class I and Class II wounds.

• Explore why PREVENA™ Therapy is the FIRST and ONLY negative pressure wound therapy device to have these clinical outcomes included in its indication statement
• Understand the impact of SSIs for high risk patients
• Overview of meta-analyses of two different negative pressure therapy systems in closed incision management

Related Presenters

Ron Silverman, FACS, MD

Before joining the company in 2010, Dr. Silverman served as Chief of Plastic Surgery at the University of Maryland School of Medicine and continues to teach as an Associate Professor there. Previously, he held academic positions at John ...

View full profile